. Author manuscript; available in PMC: 2010 Sep 3.

Published in final edited form as: Eur J Cancer. 2007 Jul 5;43(12):1849–1855. doi: 10.1016/j.ejca.2007.05.016

Table 2.

Result of HPV-testing separated at 6 and 12 month tests post-treatment

Time between treatment and recurrence (for cases)	Cases HPV^pos at 6 months	Controls HPV^pos at 6 months	OR of HPV^pos at 6 months	Cases HPV^pos at 12 months	Controls of HPV^pos at 12 months	OR of HPV^pos at 12 months
2–16.3 Years	31/189 (16%)	33/378 (9%)	2.0 (1.2–3.4)	27/181 (15%)	20/369 (5%)	2.8 (1.6–4.8)
(whole population)
2–3.6 Years	16/63 (25%)	11/126 (9%)	3.8 (1.5–9.4)	13/59 (22%)	4/123 (3%)	6.3 (2.3–17.0)
3.6–6.7 Years	10/63 (16%)	7/126 (6%)	2.0 (1.1–7.5)	8/59 (14%)	8/121 (7%)	2.1 (0.9–5.2)
>6.7 Years	5/63 (8%)	15/126 (12%)	0.6 (0.2–1.9)	6/63 (10%)	8/125 (6%)	1.4 (0.5–4.0)
Test for trend			p < 0.1			p < 0.05

Total material and divided into three groups according to time interval for recurrence of CIN2+ for cases. Odds ratios (Ors) with 95% confidence intervals.